Cannabis and psychiatric disorders: it is not only addiction

@article{Leweke2008CannabisAP,
  title={Cannabis and psychiatric disorders: it is not only addiction},
  author={F. Markus Leweke and Dagmar Koethe},
  journal={Addiction Biology},
  year={2008},
  volume={13}
}
Since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the role of this system in major psychiatric disorders like schizophrenia (SCZ), bipolar disorder (BD), major depression and anxiety disorder. Continuing in the line of earlier epidemiological studies, recent replication studies indicate that frequent cannabis use doubles the risk for psychotic symptoms and SCZ. Further points of clinical research interest are alterations of… 
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
TLDR
CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness.
Cannabinoids and schizophrenia
Prospects for the Use of Cannabinoids in Psychiatric Disorders
TLDR
The prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders are discussed, however, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking.
Endocannabinoid System and Psychiatry: In Search of a Neurobiological Basis for Detrimental and Potential Therapeutic Effects
TLDR
The eCB system plays a critical role in psychiatry; however, detrimental consequences of manipulating this endogenous system cannot be underestimated over the potential and promising perspectives of its therapeutic manipulation.
Is there a role for cannabidiol in psychiatry?
TLDR
The evidence regarding efficacy and safety of CBD in psychiatry is still scarce and larger well-designed randomised controlled trials are required to assess the effects of CBD on psychiatric disorders.
Cannabinoids and the endocannabinoid system in anxiety, depression, and dysregulation of emotion in humans.
TLDR
The most recent evidence for a therapeutic use of cannabinoids in the reviewed conditions is weak and lacking well designed RCTs, however, there is some indication of the role of the endocannabinoid system in these conditions that warrant further studies.
Therapeutic Potential of Cannabinoids in Psychosis
A systematic review of the antipsychotic properties of cannabidiol in humans
[Therapeutical use of the cannabinoids in psychiatry].
TLDR
Cannabidiol was found to have therapeutic potential with antipsychotic, anxiolytic, and antidepressant properties, in addition to being effective in other conditions, and Delta(9)-tetrahydrocannabinol and its analogues were shown to have anxIOlytic effects in the treatment of cannabis dependence.
Bipolar disorder and the endocannabinoid system
TLDR
It is suggested that activation of CB2 may stabilise mood in this disorder and basic and clinical studies to determine how cannabis and cannabinoids (CBs) can affect mood are encouraged.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?
TLDR
Combined cognitive-behavioural therapy and motivational interviewing seems a promising psychological intervention to achieve a cessation of cannabis use in patients suffering from schizophrenia.
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
TLDR
A literature review of cannabis use by patients with bipolar disorder and of the neuropharmacological properties of cannabinoids suggesting possible therapeutic effects in this condition concluded that controlled trials of these cannabinoids as adjunctive medication in bipolar disorder are now indicated.
Cannabis and neurodevelopment: implications for psychiatric disorders
  • S. Sundram
  • Psychology, Biology
    Human psychopharmacology
  • 2006
TLDR
Understanding how cannabinoids influence neurodevelopment will inform public debate about the health effects of cannabis but also open avenues in discerning how modulation of the endocannabinoid system may assist in the development of therapeutic tools for a variety of neuropsychiatric disorders.
Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression
TLDR
The data show that different medications have an impact on the expression of CB1 receptors in the ACC, and the human endogenous cannabinoid system is an appealing target in the investigation of psychiatric disorders.
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
TLDR
It is indicated that Δ-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses and warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
TLDR
The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state, and the endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects.
Health aspects of cannabis.
...
1
2
3
4
5
...